Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV
By Justice Department, Drug Enforcement Administration · Nov 11, 2026, 11:00 PM CST
On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fl
Excerpt shown under fair-use limits. Full text remains with the original publisher.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisFormal languageThe use of formal legal phrasing emphasizes authority and procedural legitimacy.
Technical detailProviding the full chemical name signals precision and aims to inform a specialized audience.
Scope definitionThe clause broadens the regulatory coverage, indicating an intent to preemptively include all possible variants.
Context
AI analysisMissing context
The excerpt does not explain the criteria used by the DEA to determine Schedule IV placement, any public comment period, or the potential impact on patients, prescribers, or law‑enforcement. It also omits background on the Improving Regulatory Transparency for New Medical Therapies Act that amended the CSA.
Important context
The scheduling decision follows an FDA approval for a new narcolepsy treatment and a recommendation from HHS, indicating coordination among federal agencies. The rule is described as an "interim final rule," suggesting it may be subject to later amendment.
Opinion vs. reporting
AI analysisThe excerpt presents factual statements about agency actions without offering opinion or analysis; it is purely reporting of regulatory events.